News and reflections from the world of AI

Aiforia aims to set a new industry standard for customer support with the launch of its one of a kind Aiforia Community Platform

Earlier this week Aiforia Technologies launched the Aiforia Community Platform — one of the only available platforms of this nature, for pathologists and scientists utilizing AI for image analysis software in preclinical and clinical settings. The company’s users, ranging from some of the world’s largest pharmaceutical companies to the world’s top ranked hospitals and medical institutions, now ...

Employee Spotlight: Interview with Tuomas Väisänen

How long have you been at Aiforia, and what do you do? I’ve been at Aiforia for two months, working as a project specialist in custom AI services. Currently, my day-to-day work is mainly focused on creating AI models for our clients. This means I get to be at the forefront of research in teaching AI models to identify various elements in whole slide images.

Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics

Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast ...

Employee Spotlight: Interview with Ville Lehtonen

How long have you been at Aiforia, and what do you do? I joined Aiforia in mid-January 2022 so I've now been an Aiforian for almost 2 months. I'm working as the team lead in our integrations team, meaning that I'm responsible for a little bit of everything. My responsibilities include e.g. coordinating the team, meeting with clients, handling different administrative tasks, agile project ...

Benefits of AI in preclinical studies

The preclinical phase of drug discovery involves extensive safety evaluations of the potential therapeutic intervention, often using cell and animal models of disease. These studies commonly include going through numerous histopathological samples. This contributes to the drug development process being time-consuming and labor-intensive for pharmaceutical and contract research organizations.

AI-assisted image analysis of neurodegenerative disease markers

Introduction Alzheimer’s disease (AD) is the most common cause of dementia, attributed to its characteristic symptoms of brain shrinkage and cell death. Onset of the diseases is thought to be due to abnormal buildup of amyloid-β (Aβ), a protein in the brain, creating plaques and leading to neurodegeneration. Similarly, Aβ buildup can cause cerebral amyloid angiopathy (CAA), a condition which ...